Bexion Pharmaceuticals Presents BXQ-350 Data in Metastatic Colorectal Cancer at ASCO GI 2025
Key Insights
Bexion Pharmaceuticals (search) will present a poster on BXQ-350 in combination with mFOLFOX7 (search) and bevacizumab for metastatic colorectal cancer (search) at the ASCO GI 2025.
BXQ-350 is a first-in-class biologic that modulates sphingolipid (search) metabolism and has shown single-agent activity across multiple solid tumor types.
The Phase 1b/2 study evaluates BXQ-350 with standard of care in newly diagnosed metastatic colorectal cancer (search) patients, with plans to proceed to a randomized, double-blinded, placebo-controlled phase.
Bexion Pharmaceuticals (search), Inc. is set to present a poster at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) held January 23-25, 2025, in San Francisco, CA, showcasing the ongoing Phase 1b/2 study of BXQ-350 in combination with mFOLFOX7 (search) and bevacizumab for newly diagnosed metastatic colorectal cancer (search) (mCRC) patients.
The poster presentation, titled "BXQ-350, a novel sphingolipid (search) metabolism modulator, in combination with mFOLFOX7 (search) and bevacizumab in newly diagnosed metastatic colorectal cancer (search) (mCRC) patients: A phase 1b/2 study," highlights the trial's progress in evaluating the safety and efficacy of BXQ-350, Bexion's lead drug candidate.
About BXQ-350
BXQ-350 represents a first-in-class biologic approach, containing the multifunctional sphingolipid (search) activator protein, Saposin C, and a phospholipid. Prior Phase 1 clinical trials have established a robust safety profile in both adult and pediatric patients, with evidence of single-agent activity across various solid tumor types. Preclinical and clinical data also suggest potential therapeutic benefits in chemotherapy-induced peripheral neuropathy (search) (CIPN), a significant unmet need for patients undergoing treatment with oxaliplatin and other chemotoxic agents.
Clinical Trial Details
The Phase 1b/2 study is designed to assess the combination of BXQ-350 with the standard-of-care regimen, mFOLFOX7 (search) and bevacizumab, in patients with newly diagnosed mCRC. Bexion has completed enrollment in the open-label portion of the study and is preparing to advance to the randomized, double-blinded, placebo-controlled phase. The study aims to evaluate the drug's impact on tumor response, progression-free survival, and overall survival, while also monitoring potential adverse effects.
Bexion's Broader Pipeline
Beyond mCRC, Bexion Pharmaceuticals (search) is exploring the potential of BXQ-350 in other solid tumors, including high-grade gliomas and pediatric brain tumors. The company has also completed enrollment in a proof-of-concept trial for CIPN, further expanding the therapeutic applications of its lead drug candidate.